These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9527807)

  • 41. Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney.
    Muirhead MR; Somogyi AA
    Drug Metab Dispos; 1991; 19(2):312-6. PubMed ID: 1676629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transepithelial transport of levofloxacin in the isolated perfused rat kidney.
    Ito T; Yano I; Hashimoto Y; Inui K
    Pharm Res; 2000 Feb; 17(2):236-41. PubMed ID: 10751041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. No effect of probenecid on the renal and biliary clearances of digoxin in man.
    Hedman A; Angelin B; Arvidsson A; Dahlqvist R
    Br J Clin Pharmacol; 1991 Jul; 32(1):63-7. PubMed ID: 1888643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacokinetic properties of ofloxacin (review of the literature].
    Iakovlev VP
    Antibiot Khimioter; 1996; 41(9):24-32. PubMed ID: 9005781
    [No Abstract]   [Full Text] [Related]  

  • 45. The effects of probenecid on the excretion kinetics of stanozolol, an anabolic steroid, in rats.
    Ryu JC; Kwon OS; Song YS; Yang JS; Park J
    J Appl Toxicol; 1992 Dec; 12(6):385-91. PubMed ID: 1452971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
    Lee LJ; Hafkin B; Lee ID; Hoh J; Dix R
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2196-200. PubMed ID: 9333047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereoselectivity of ofloxacin intestinal transport in the rat.
    Rabbaa L; Dautrey S; Colas-Linhart N; Carbon C; Farinotti R
    Drugs; 1995; 49 Suppl 2():333-4. PubMed ID: 8549352
    [No Abstract]   [Full Text] [Related]  

  • 48. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
    Ward ES; Pollack GM; Brouwer KL
    Drug Metab Dispos; 2000 Dec; 28(12):1433-9. PubMed ID: 11095580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The uptake of nalidixic acid and enoxacin by rat renal cortical slices in rat].
    Oda M; Sasaya M; Hirano T; Nakajima Y; Iwata K; Chiba K; Miyazaki S; Takada M
    Yakugaku Zasshi; 1995 May; 115(5):394-9. PubMed ID: 7595867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
    Tahara H; Kusuhara H; Chida M; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1187-94. PubMed ID: 16291876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal handling of cisplatin: interactions with organic anions and cations in the dog.
    Klein J; Bentur Y; Cheung D; Moselhy G; Koren G
    Clin Invest Med; 1991 Oct; 14(5):388-94. PubMed ID: 1742916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
    Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
    Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans.
    Somogyi AA; Bochner F; Sallustio BC
    Clin Pharmacol Ther; 1992 Apr; 51(4):379-87. PubMed ID: 1563208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions.
    Sörgel F; Kinzig M
    Am J Med; 1993 Mar; 94(3A):56S-69S. PubMed ID: 8383921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.
    Rabbaa L; Dautrey S; Colas-Linhart N; Carbon C; Farinotti R
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2126-30. PubMed ID: 8878593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey.
    Okazaki O; Kurata T; Hakusui H; Tachizawa H
    Xenobiotica; 1992 Apr; 22(4):439-50. PubMed ID: 1523865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Transformation of S- (+)-ofloxacin enantiomer in human body and determination by synchronous-derivative fluorimetry].
    Gong QJ; Jin WJ; Dong C
    Guang Pu Xue Yu Guang Pu Fen Xi; 2001 Oct; 21(5):688-90. PubMed ID: 12945333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N
    Müller F; Hohl K; Keller S; Schmidt-Gerets S; Deutsch B; Schuler-Metz A; Fromm MF; Stopfer P; Gessner A
    Clin Pharmacol Ther; 2023 May; 113(5):1070-1079. PubMed ID: 36636898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients.
    Fuhrmann V; Schenk P; Mittermayer C; El Menyawi I; Ratheiser K; Thalhammer F
    Am J Kidney Dis; 2003 Aug; 42(2):310-4. PubMed ID: 12900813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.